Eiko Lifesciences Limited - chemicals and materials in Thane, Maharashtra, India. FY 2026 financials & compliance.
CIN L65993MH1977PLC258134 Incorporated 07 January 1977 ROC Mumbai HQ Thane, Maharashtra, India
Active Listed - BSE: 540204 Public Limited Company chemicals and materials MSME · Small
Market Cap
₹74.70 Cr
EIKO · BSE
Share Price
₹49.23
-3.45% today
Revenue
₹52.57 Cr
FY 2025-26 · +39.6% YoY
EBITDA
₹7.32 Cr
Margin 13.9%
Net Profit
₹5.31 Cr
FY 2025-26 · +185.5% YoY
P/E (TTM)
14.4x
P/B 1.0x
ROE
8.5%
ROCE 11.2%
Debt / Equity
0.06
Interest cover 5.7x

About Eiko Lifesciences Limited

Data last updated:

Eiko Lifesciences Limited is a public limited company based in Thane, Maharashtra, India. It operates in the specialty chemicals segment of the chemicals and materials sector. It was incorporated on 07 January 1977 and has been in existence for over 49 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L65993MH1977PLC258134. Its GSTIN is 27AAACN0917C1ZZ (Maharashtra). It is a listed company as per MCA records. Its shares are listed on BSE: 540204.

The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹14.65 Cr. It was formerly known as Ornate Ventures Limited and Narendra Investments (Delhi) Limited. It is led by directors including Umesh Ravindranath More (Whole-Time Director) and Sumukh Prabhakar Vartak (Whole-Time Director).

Its last annual general meeting (AGM) was held on 05 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 604 Centrum Opp. Tmc Office Near Satkar Grande Hotel Wagle Estate, Thane, Maharashtra, India – 400604.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹52.57 Cr, a growth of 39.6% compared to the previous year. For the same year it recorded a net profit of ₹5.31 Cr (net margin 10.1%) and EBITDA of ₹7.32 Cr (EBITDA margin 13.9%). The net worth stands at ₹68.79 Cr (up 21.1% YoY). Total assets are valued at ₹74.56 Cr (up 24.7% YoY).

The company is associated with 2 brands: Eiko LifeSciences Limited and Narendra Investments. As per MCA filings, the company has open charges of ₹10 Cr and satisfied charges of ₹8 Cr on record. The company has 48 deals on record (47 market trades, 1 funding round), with disclosed funding of ₹24.95 Cr; the latest was in June 2025. Its 7 peer companies in the Chemicals industry (API Manufacturers, Lifesciences, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 4 smaller; the largest is Allegro Speciality Chemicals Private Limited with revenue of ₹38.95 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2021, listing 6 overdue payments to 2 micro and small suppliers.

Eiko Lifesciences Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-33-0313779). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website eikolifesciences.com.

Company details

CIN L65993MH1977PLC258134
Registration Number 258134
Incorporation Date 07 January 1977
ROC Mumbai
Listing Status Listed - Listed on BSE (540204)
Company Status Active
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-MH-33-0313779

Name history

Eiko Lifesciences has undergone 4 name changes throughout its history. The current legal name is Eiko Lifesciences Limited.

Company NameStatus
Eiko Lifesciences LimitedCurrent
Ornate Ventures LimitedPrevious
Narendra Investments (Delhi) LimitedPrevious
Odin Ventures LimitedPrevious

CIN history

Eiko Lifesciences has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L65993MH1977PLC258134, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L65993MH1977PLC258134Current
L65993DL1977PLC008460Previous
U65993DL1977PLC008460Previous

Recognitions & Rankings of Eiko Lifesciences

MSME (Udyam registered) Ministry of MSME
Category
Small (2024-25)
Udyam number
UDYAM-MH-33-0313779

Contact details

Eiko Lifesciences Limited's registered office is in Thane, Maharashtra. Its website is eikolifesciences.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    604 Centrum Opp. Tmc Office Near Satkar Grande Hotel Wagle Estate, Thane, Maharashtra, India – 400604
  • Industry
    Chemicals and Materials, Specialty Chemicals

To see the full contact details of Eiko Lifesciences Limited, buy the company report.

Comprehensive company report
Eiko Lifesciences Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Eiko Lifesciences operates two associated brands: Eiko LifeSciences Limited and Narendra Investments. Each brand links to its own profile.

BrandDescriptionWebsite
Functions as an investment management firm handling diversified funds and portfolios.narendrainvestment.com
Manufacturing and exporting of speciality chemicals and pharma intermediates in India.eikolifesciences.com

Business activity

The main business activity of Eiko Lifesciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Eiko Lifesciences Limited, buy the company report.

Financials of Eiko Lifesciences Limited

FY 2025-26 filings available

Eiko Lifesciences Limited reported revenue of ₹52.57 Cr (up 39.6% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹52.57 Cr
+39.6% YoY
EBITDA
₹7.32 Cr
+165.2% YoY
Profit After Tax
₹5.31 Cr
+185.5% YoY
Net Worth
₹68.79 Cr
+21.1% YoY
Total Assets
₹74.56 Cr
+24.7% YoY
Total Debt
₹4.73 Cr
+71.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2019-20FY 2018-19FY 2017-18
Income statement
Revenue52.5737.6610.404.272.36
Revenue growth+39.6%-+143.6%+80.9%-
EBITDA7.322.76(4.50)(0.68)0.37
EBITDA margin+13.9%+7.3%-43.3%-15.9%+15.7%
Profit before tax7.103.05(4.92)(1.00)0.24
Net profit5.311.86(1.89)(0.45)0.19
Net profit margin+10.1%+4.9%-18.2%-10.5%+8.1%
EPS (₹)3.711.68(4.99)0.000.51
Balance sheet
Total assets74.5659.772.726.177.53
Net worth68.7956.792.954.925.56
Total debt4.732.761.611.371.74
Cash & bank13.6111.780.020.110.80
Net working capital33.6927.38(4.31)1.042.57
Cash flow
Cash from operations2.252.78(0.33)0.160.00
Cash from investing(8.63)(11.30)(0.71)(0.30)0.00
Cash from financing8.216.960.95(0.55)0.00
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue17.7216.7518.3411.9811.6710.7111.277.49
Revenue growth (YoY)+51.8%+56.4%+62.7%+60.0%+43.0%-0.4%--
Other income0.240.450.130.350.300.270.640.12
EBITDA2.231.942.261.871.761.511.310.64
EBITDA margin+12.6%+11.6%+12.3%+15.6%+15.1%+14.1%+11.6%+8.5%
Depreciation0.260.250.250.260.260.250.250.16
Interest0.160.130.120.070.100.050.070.03
Profit before tax2.052.012.021.891.701.481.630.57
Tax0.500.490.520.470.420.370.390.14
Net profit1.551.521.501.421.281.111.240.43
EPS (₹)0.780.760.860.880.780.660.800.32
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue42.1332.4927.9318.3225.4111.990.00
Revenue growth+29.7%+16.3%+52.5%-27.9%+111.9%--
EBITDA3.371.711.620.961.320.52(0.17)
EBITDA margin+8.0%+5.3%+5.8%+5.2%+5.2%+4.3%-
Profit before tax4.722.320.991.020.950.830.13
Net profit3.591.310.760.740.720.610.13
Net profit margin+8.5%+4.0%+2.7%+4.0%+2.8%+5.1%-
EPS (₹)2.501.260.580.920.851.610.33
Balance sheet
Total assets69.1758.1850.6829.4833.2614.355.74
Net worth67.5156.4250.6829.4328.6312.535.48
Total debt1.671.750.000.054.631.830.26
Cash & bank13.5511.5113.350.610.224.070.02
Net working capital25.5927.0529.438.1511.018.442.14
Cash flow
Cash from operations6.922.05(7.08)4.22(7.73)(0.83)0.77
Cash from investing(11.21)(9.85)(0.55)0.870.59(2.94)(0.65)
Cash from financing6.335.9720.36(4.70)3.287.81(0.13)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue14.6614.1815.909.579.207.457.096.91
Revenue growth (YoY)+59.4%+90.3%+124.3%+38.5%+18.9%-30.7%--
Other income0.480.680.450.560.560.550.870.10
Total expenses13.4913.2714.688.708.486.936.586.46
EBITDA1.170.911.220.870.720.520.510.45
EBITDA margin+8.0%+6.4%+7.7%+9.1%+7.8%+7.0%+7.2%+6.5%
Depreciation0.150.150.150.150.150.150.150.15
Interest0.070.040.040.040.070.020.040.02
Profit before tax1.431.401.481.241.060.901.190.38
Tax0.320.340.370.290.250.220.300.10

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 18 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue17.7216.7518.3411.9811.6710.7111.277.49
Revenue growth (YoY)+51.8%+56.4%+62.7%+60.0%+43.0%-0.4%--
Other income0.240.450.130.350.300.270.640.12
EBITDA2.231.942.261.871.761.511.310.64
EBITDA margin+12.6%+11.6%+12.3%+15.6%+15.1%+14.1%+11.6%+8.5%
Depreciation0.260.250.250.260.260.250.250.16
Interest0.160.130.120.070.100.050.070.03
Profit before tax2.052.012.021.891.701.481.630.57
Tax0.500.490.520.470.420.370.390.14
Net profit1.551.521.501.421.281.111.240.43
EPS (₹)0.780.760.860.880.780.660.800.32
ParticularsFY 2025-26FY 2024-25FY 2019-20FY 2018-19FY 2017-18
Revenue52.5737.6610.404.272.36
Revenue growth+39.6%-+143.6%+80.9%-
Other income1.161.200.010.040.04
Total expenses45.2534.9014.904.951.99
Employee cost0.480.292.580.780.18
EBITDA7.322.76(4.50)(0.68)0.37
EBITDA margin+13.9%+7.3%-43.3%-15.9%+15.7%
Depreciation1.020.740.190.170.08
Interest0.360.170.240.190.09
Profit before tax7.103.05(4.92)(1.00)0.24
Tax1.790.75(1.32)(0.21)0.05
Net profit5.311.86(1.89)(0.45)0.19
Net profit margin+10.1%+4.9%-18.2%-10.5%+8.1%
EPS (₹)3.711.68(4.99)0.000.51
ParticularsFY 2025-26FY 2024-25FY 2019-20FY 2018-19FY 2017-18
Equity & liabilities
Share capital14.3513.763.823.823.82
Reserves & surplus50.3843.03(0.87)1.101.74
Shareholders' funds (net worth)68.7956.792.954.925.56
Minority interest1.050.22(1.83)(0.12)0.22
Secured loans4.732.761.611.371.74
Unsecured loans0.000.000.000.000.00
Total debt4.732.761.611.371.74
Total liabilities74.5659.772.726.177.53
Assets
Gross block25.9525.951.751.712.27
Net block22.1023.111.751.711.69
Capital work in progress0.000.000.000.000.00
Investments15.297.150.101.723.17
Inventories3.975.773.212.313.10
Sundry debtors20.2210.791.180.861.46
Cash & bank balances13.6111.780.020.110.80
Loans & advances9.604.540.620.890.61
Total current assets47.4032.885.034.175.97
Total current liabilities13.715.509.343.133.40
Net working capital33.6927.38(4.31)1.042.57
Total assets74.5659.772.726.177.53
ParticularsFY 2025-26FY 2024-25FY 2019-20FY 2018-19FY 2017-18
Opening cash11.7813.350.110.800.00
Net cash from operating activities2.252.78(0.33)0.160.00
Net cash from investing activities(8.63)(11.30)(0.71)(0.30)0.00
Net cash from financing activities8.216.960.95(0.55)0.00
Net change in cash1.83(1.57)(0.09)(0.69)0.00
Closing cash13.6111.780.020.110.80
ParticularsFY 2025-26FY 2024-25FY 2019-20FY 2018-19FY 2017-18
Growth
Sales growth+39.6%-+143.6%+80.9%-
EBITDA growth+165.2%--561.8%-283.8%-
PBT growth+132.8%+9998.0%-392.0%-+9997.0%
Net income growth+185.5%--320.0%-336.8%-
Revenue CAGR (3Y)+130.9%+151.8%---
EBITDA CAGR (3Y)-+95.4%---
Profitability & leverage
Net income margin+10.1%+6.1%-34.6%-18.5%+8.1%
Return on capital employed+11.2%+4.8%0.0%0.0%+4.7%
Return on net worth+8.5%+3.3%0.0%0.0%+3.6%
Debt / equity0.060.050.380.300.31
Long-term debt / equity0.040.040.260.090.09
Interest cover5.718.42-5.12-22.3531.03
Efficiency & per share
Fixed asset turnover2.031.456.012.151.04
Inventory turnover10.796.533.771.580.76
Debtors turnover3.393.4910.203.681.62
EPS (₹)3.711.68(4.99)0.000.51
Dividend per share (₹)0.000.000.000.000.00
Book value per share (₹)45.1241.267.7112.8914.56
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue14.6614.1815.909.579.207.457.096.91
Revenue growth (YoY)+59.4%+90.3%+124.3%+38.5%+18.9%-30.7%--
Other income0.480.680.450.560.560.550.870.10
Total expenses13.4913.2714.688.708.486.936.586.46
EBITDA1.170.911.220.870.720.520.510.45
EBITDA margin+8.0%+6.4%+7.7%+9.1%+7.8%+7.0%+7.2%+6.5%
Depreciation0.150.150.150.150.150.150.150.15
Interest0.070.040.040.040.070.020.040.02
Profit before tax1.431.401.481.241.060.901.190.38
Tax0.320.340.370.290.250.220.300.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue42.1332.4927.9318.3225.4111.990.00
Revenue growth+29.7%+16.3%+52.5%-27.9%+111.9%--
Other income2.131.370.180.850.670.460.43
Total expenses38.7630.7826.3117.3624.0911.470.17
Employee cost0.230.220.160.230.230.120.07
EBITDA3.371.711.620.961.320.52(0.17)
EBITDA margin+8.0%+5.3%+5.8%+5.2%+5.2%+4.3%-
Depreciation0.590.630.660.630.560.060.06
Interest0.190.130.150.160.480.090.07
Profit before tax4.722.320.991.020.950.830.13
Tax1.130.570.230.260.230.220.00
Net profit3.591.310.760.740.720.610.13
Net profit margin+8.5%+4.0%+2.7%+4.0%+2.8%+5.1%-
EPS (₹)2.501.260.580.920.851.610.33
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital14.3513.7612.878.328.323.823.82
Reserves & surplus49.1042.6637.8121.1120.312.371.66
Shareholders' funds (net worth)67.5156.4250.6829.4328.6312.535.48
Secured loans1.671.750.000.053.080.200.26
Unsecured loans0.000.000.000.001.551.630.00
Total debt1.671.750.000.054.631.830.26
Total liabilities69.1758.1850.6829.4833.2614.355.74
Assets
Gross block16.9916.9915.6915.3415.120.520.52
Net block13.6714.2613.5613.8814.290.250.31
Capital work in progress0.000.000.000.000.000.000.00
Investments15.157.074.020.050.200.220.50
Inventories3.974.023.390.915.460.060.00
Sundry debtors18.8910.1413.137.114.563.410.00
Cash & bank balances13.5511.5113.350.610.224.070.02
Loans & advances2.042.901.060.672.203.162.14
Total current assets38.4528.5730.939.3012.4410.702.16
Total current liabilities12.861.521.501.151.432.260.02
Net working capital25.5927.0529.438.1511.018.442.14
Total assets69.1758.1850.6829.4833.2614.355.74
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash11.5113.350.610.224.070.020.03
Net cash from operating activities6.922.05(7.08)4.22(7.73)(0.83)0.77
Net cash from investing activities(11.21)(9.85)(0.55)0.870.59(2.94)(0.65)
Net cash from financing activities6.335.9720.36(4.70)3.287.81(0.13)
Net change in cash2.04(1.83)12.730.40(3.85)4.05(0.01)
Closing cash13.5511.5113.350.610.224.070.02
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+29.7%+16.3%+52.5%-27.9%+111.9%--
EBITDA growth+97.1%+5.6%+68.8%-27.3%+153.9%+405.9%-
PBT growth+103.5%+134.3%-2.9%+7.4%+14.5%+538.5%+18.2%
Net income growth+174.1%+72.4%+2.7%+2.8%+18.0%+369.2%-
Revenue CAGR (3Y)+32.0%+8.5%+32.6%-+302.4%+186.5%-100.0%
EBITDA CAGR (3Y)+52.0%+9.0%+46.1%-+87.6%+16.4%-
Profitability & leverage
Net income margin+8.5%+5.4%+2.7%+4.2%+2.8%+5.1%-
Return on capital employed+7.7%+3.8%+2.8%+3.8%+6.0%+9.2%+3.5%
Return on net worth+5.8%+2.4%+1.9%+2.7%+3.5%+6.8%+2.4%
Debt / equity0.030.020.000.080.160.120.05
Long-term debt / equity0.010.010.000.000.000.020.04
Interest cover6.8312.0415.6348.4863.1619.57-30.43
Efficiency & per share
Fixed asset turnover2.481.991.801.203.2523.060.00
Inventory turnover10.558.7712.995.759.21399.670.00
Debtors turnover2.902.792.763.146.387.030.00
EPS (₹)2.501.260.580.920.851.610.33
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)44.2241.0039.3735.3834.4316.1914.35

To see the full year-wise statements and ratios of Eiko Lifesciences Limited, buy the company report.

Board of directors and KMP of Eiko Lifesciences Limited

Eiko Lifesciences Limited currently reports 8 directors and 1 key managerial person. 21 former directors have served the organization.

Current Directors and KMP
NameDesignationAppointment DateTenureStatus
Bhavesh Dhirajlal TannaDirector26 Aug 201313 Years 2 MonthsCurrent
Jaid Ismail KojarCfo09 Feb 20224 Years 9 MonthsCurrent
Umesh Ravindranath MoreWhole-Time Director12 Nov 20206 Years 0 MonthsCurrent
Kajal Dhanpatraj KothariDirector09 Sep 20206 Years 2 MonthsCurrent
Laxmikant Ramprasad KabraDirector26 Aug 201313 Years 2 MonthsCurrent
Sumukh Prabhakar VartakWhole-Time Director29 Jul 20251 Years 3 MonthsCurrent
Showing 6 of 9 current directors and KMP. View all directors and KMP

Peer comparison

Eiko Lifesciences Limited is compared with the 7 companies closest to it by revenue in the Chemicals industry (API Manufacturers, Lifesciences, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Eiko Lifesciences Limitedthis company₹52.57 Cr (FY 2026)₹5.31 Cr10.1%39.6%Thane, Maharashtra, India
Allegro Speciality Chemicals Private Limited₹38.95 Cr (FY 2025)-21.0%Hyderabad, Telangana, India
Blue Star Extrusion Private Limited₹38.76 Cr (FY 2025)83.0%Sangli, Maharashtra, India
Nebula Healthcare Limited₹38.59 Cr (FY 2025)4.0%Ahmedabad, Gujarat, India
Almon Healthcare Private Limited₹38.26 Cr (FY 2025)58.0%Ahmedabad, Gujarat, India
Vadivarhe Speciality Chemicals Limited₹38.17 Cr (FY 2025)-6.0%Igatpuri, Maharashtra, India
Leomine Organics Private Limited₹38.15 Cr (FY 2025)82.0%Mumbai, Maharashtra, India
Resipol Adhesives Private Limited₹38.08 Cr (FY 2025)-64.0%Kadi, Gujarat, India

To see the full peer comparison of Eiko Lifesciences Limited, buy the company report.

Auditor

Eiko Lifesciences Limited is audited by Thanawala & Company for the financial year 2023.

Auditor firmFinancial yearFirm registration number
Thanawala & CompanyFY 2023110948W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 39.90%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 60.10%.

Promoters: 39.90%Retail & Others: 60.10%
Sep 2026
QUARTER
39.90% Promoters
60.10% Retail & Others
Promoter holding - history
Now 39.90% · Sep 2026High 39.90% · Jun 2026Low 37.20% · Dec 2025
36%37.3%38.5%39.8%41%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 37.20%Mar 2026: 37.20%Jun 2026: 39.90%Sep 2026: 39.90%39.90%37.20%39.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters39.90%39.90%37.20%37.20%
Public60.10%60.10%62.80%62.80%

Charges & borrowings

Open charges
₹10 Cr
Satisfied charges
₹8 Cr
Breakdown by lending institutions
Bank of India₹10.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
30 Sep 2025101172739Bank of India₹10 CrOpen
30 Nov 2024101031353Others₹1 CrSatisfied
13 May 2021100452692Others₹7 CrSatisfied

To see the full charge records of Eiko Lifesciences Limited, buy the company report.

Total charge records: 3 View all charges

Deals & funding

Eiko Lifesciences Limited has 48 deals on record (47 market trades, 1 funding round), with disclosed funding of ₹24.95 Cr; the latest was in June 2025.

Total deals
48
Market trades
47
Funding round
1
Disclosed funding
₹24.95 Cr

Deals on record (5 of 48)

WhenDealAmountParties
Mar 2025Market trade₹70.8 LakhBuyer: an individual
Seller: 2B Black Bio LLP
Feb 2025Market trade₹37 LakhBuyer: an individual
Seller: 2B Black Bio LLP
Apr 2024Market trade₹1.06 CrBuyer: V Square Pharmachem Private Limited
Seller: an individual
Mar 2024Market trade₹99.5 LakhBuyer: V Square Pharmachem Private Limited
Seller: an individual
Aug 2023Market trade₹26.1 LakhSeller: Dhwaja Shares & Securities Private Limited

To see the full deal history of Eiko Lifesciences Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Eiko Lifesciences Limited has 1 MSME Form 1 return on record for the period ending Mar 2021, listing 6 overdue payments to 2 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (2 of 2)

SupplierAmount dueDue sinceReported on
Omkar Speciality Chemicals Limited
Delicare Lifesciences Private Limited

To see the full MSME payment records of Eiko Lifesciences Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

GST

Eiko Lifesciences has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
27AAACN0917C1ZZMaharashtraActive01 Jul 2017

To see the full GST registrations and return filing status of Eiko Lifesciences Limited, buy the company report.

Recent activity

Eiko Lifesciences Limited has 28 board changes on record since 2011: 9 appointments and 19 cessations. The latest: Suraj Mahadev Gaikwad was appointed as Additional Director on 24 Aug 2026.

Appointed
Suraj Mahadev Gaikwad was appointed as Additional Director.
Filing
Eiko Lifesciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai Ii.
Charges
A charge with Bank Of India of Rs. 10.00 Cr registered on 30 Sep 2025 with Charge ID 101172739 was modified on 24 Nov 2025.
Charges
A charge registered on 30 Nov 2024 via Charge ID 101031353 with Others was fully satisfied on 06 Oct 2025.
Charges
A charge with Bank Of India amounted to Rs. 10.00 Cr with Charge ID 101172739 was registered on 30 Sep 2025.
AGM
Eiko Lifesciences Limited last Annual general meeting of members was held on 05 Sep 2025 as per latest MCA records.
Appointed
Sumukh Prabhakar Vartak was appointed as Whole-Time Director.
Charges
A charge with Others amounted to Rs. 1.00 Cr with Charge ID 101031353 was registered on 30 Nov 2024.
Appointed
Hasti Arjav Doshi was appointed as Director.
Charges
A charge registered on 13 May 2021 via Charge ID 100452692 with Others was fully satisfied on 05 Sep 2022.
Appointed
Jaid Ismail Kojar was appointed as CFO.
Ceased
Chintan Bharatbhai Doshi ceased to be Company Secretary.

25 earlier events are in the company report.

Frequently asked questions

Eiko Lifesciences is an active public limited company based in Thane, Maharashtra, India. The company works in specialty chemicals, within the chemicals and materials industry. It was incorporated on 07 January 1977 (49+ years old) and is registered under CIN L65993MH1977PLC258134. Listed on BSE: 540204.

Eiko Lifesciences reported revenue of ₹52.57 Cr for FY 2025-26 (up 39.6% YoY) based on consolidated financials.

Eiko Lifesciences has 9 current directors and KMP:

The latest financial statements of Eiko Lifesciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 05 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Eiko Lifesciences is 27AAACN0917C1ZZ, registered in Maharashtra.

The CIN (Corporate Identification Number) of Eiko Lifesciences is L65993MH1977PLC258134. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Eiko Lifesciences is a listed company as per MCA records. Its shares are listed on BSE (code: 540204).

Eiko Lifesciences was incorporated on 07 January 1977, making it 49+ years old. It is registered with the Registrar of Companies, Mumbai.

Eiko Lifesciences has 48 deals on record (47 market trades, 1 funding round), with disclosed funding of ₹24.95 Cr; the latest was in June 2025.

The peers of Eiko Lifesciences by revenue are Allegro Speciality Chemicals Private Limited, Blue Star Extrusion Private Limited, Nebula Healthcare Limited, Almon Healthcare Private Limited, Vadivarhe Speciality Chemicals Limited and 2 more, all in the Chemicals industry (API Manufacturers, Lifesciences, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Suraj Mahadev Gaikwad was appointed as Additional Director on 24 Aug 2026. Sumukh Prabhakar Vartak was appointed as Whole-Time Director on 29 Jul 2025. Hasti Arjav Doshi was appointed as Director on 03 Sep 2024. Eiko Lifesciences has 28 board changes on record in total.

Yes, Eiko Lifesciences is registered as a small enterprise under Udyam registration (number: UDYAM-MH-33-0313779).